How AstraZeneca Is Playing Its Cancer Cards To Become An $80 ... Japan, the U.K. and the U.S. each year, Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced it has expanded its patient support offerings to include AZhelps, a comprehensive and unique program that helps patients manage ...

We expect AstraZeneca AZN to beat expectations when it reports second-quarter 2023 results on Jul 28. In the last reported quarter, the company delivered an earnings surprise of 11.63%.

In collaboration with AstraZeneca and Genpact, the company’s business process outsourcing partner, Trintech implemented its Certification solution to manage reconciliations of AstraZeneca’s ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

Job titles can often disappear in the tech jargon and bureaucracy of the corporate world. Yet, it’s worth noting what’s on the business card for Mark Clare (pictured, left). He’s the head of da ...

The approval is for a COPD medicine; the sale involves a gout treatment. AstraZeneca has received Food And Drug Administration approval for one product, and entered into a deal to sell the U.S ...

AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug.